FindTrial
Sign In

Intravitreal Bevacizumab for Diabetic Macular Edema

Status
UNKNOWN
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00703235
Enrollment
Unknown
Registered
2008-06-23
Start date
Unknown
Completion date
Unknown
Last updated
2008-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Retinopathy, Macular Edema

Brief summary

Diabetic macular edema is a common cause of visual loss among diabetic patients. Studies have demonstrated the role of vascular endothelial growth factor (VEGF) in the pathogenesis of edema. This study designed to evaluate the effect of Intravitreal injection of a recombinant monoclonal anti-VEGF antibody, Bevacizumab, for treatment of diabetic macular edema.

Interventions

DRUGBevacizumab

Sponsors

Isfahan Ophthalmology Research Center
Lead SponsorNETWORK

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Diabetes mellitus * Clinically significant macular edema * Possibility of performing macular OCT * Consent of patient for inclusion in the study

Exclusion criteria

* History of macular photocoagulation in less than 6 months of inclusion in the study * Necessity of surgical intervention * Rejection of the remaining in the study by patient

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026